A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820 · tracked via the Priya Life Science UK tracker

Sponsor

Pfizer

Phase

Phase 2

Started

2025-11-10

Last updated

2026-08-25

Condition(s) studied

Pulmonary Hypertension

Investigational drug(s) / intervention(s)

PF-07868489

PF-07868489: Participants will receive subcutaneous doses of PF-07868489 every 4 weeks

Study summary

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart.

This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

This study is seeking participants who are: * aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study. * willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * do not have worsening or hospitalization for worsening PAH during the qualifying study. * not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH. * do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study. * not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem). * not currently prescribed or taking medicines called as GLP-1 agonist.

Primary outcome measure(s)

Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — Baseline up to week 111
Number of Participants With Change From Baseline in Laboratory Tests Results — Baseline up to week 111
Number of Participants With Vital Sign Abnormalities — Baseline up to week 111

Trial sites (27)

Facility	City	Region
UCSF Health St. Mary's Hospital	San Francisco	California
Heart and Vascular Center	San Francisco	California
UCSF Helen Diller Medical Center at Parnassus Heights	San Francisco	California
Mount Sinai Hospital	New York	New York
Royal Prince Alfred Hospital	Camperdown	New South Wales
Pulmonary Hypertension Research Queensland Pty Ltd	Auchenflower	Queensland
HUB Hôpital Erasme	Brussels	Belgium
UZ Leuven	Leuven	Belgium
Guangdong Provincial People's Hospital	Guangzhou	Guangdong
The Second Xiangya Hospital of Central South University	Changsha	Hunan
Zhongda Hospital Southeast University	Nanjing	Jiangsu
Shanghai Pulmonary Hospital	Shanghai	Shanghai Municipality
Vseobecna fakultni nemocnice v Praze	Prague	Czechia
Thoraxklinik-Heidelberg gGmbH	Heidelberg	Baden-Wurttemberg
Universitätsklinikum Regensburg	Regensburg	Bavaria
Universitaetsklinikum Giessen und Marburg GmbH	Giessen	Hesse
Universitätsmedizin Greifswald	Greifswald	Mecklenburg-Vorpommern
Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden	Dresden	Saxony
Kobe University Hospital	Kobe	Hyōgo
St. Marianna University Hospital	Kawasaki	Kanagawa
National Hospital Organization Okayama Medical Center	Okayama	Japan
Gachon University Gil Medical Center	Incheon	Incheon-gwangyeoksi [incheon]
Seoul National University Hospital	Seoul	Seoul-teukbyeolsi [seoul]
Severance Hospital, Yonsei University Health System	Seoul	Seoul-teukbyeolsi [seoul]
Samsung Medical Center	Seoul	Seoul-teukbyeolsi [seoul]
Hospital Universitario 12 de Octubre	Madrid	Spain
Hammersmith Hospital	London	Greater London

More Pfizer trials in the UK

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC Active, not recruiting

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Active, not recruiting

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 Active, not recruiting

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) Active, not recruiting

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). Active, not recruiting

Other trials for the same condition

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD Active, not recruiting

A Study of Mosliciguat in PH-ILD Active, not recruiting

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Enrolling by invitation

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07073820 on ClinicalTrials.gov ↗ ← All trials in the UK